Document is current
Any future updates will be listed below
-
Authors
Kim, Yoon Jeon
Sivaprasad, Sobha https://orcid.org/0000-0001-8952-0659
Aslam, Tariq https://orcid.org/0000-0002-9739-7280
Jaki Mekjavić, Polona
Balčiūnienė, Vilma Jūratė
Visser, Linda
Joussen, Antonia M.
Yoon, Young Hee https://orcid.org/0000-0002-2849-7528
Lai, Timothy Y. Y. https://orcid.org/0000-0002-7832-6428
Okada, Annabelle A.
- License Information
-
More Information
Article History
Received: 15 July 2024
Revised: 13 June 2025
Accepted: 17 June 2025
First Online: 4 July 2025
Competing interests
: Yoon Jeon Kim: None. Sobha Sivaprasad: Received funding/fees from AbbVie, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, EyeBio, EyePoint, Iveric Bio, Janssen, Kriya Therapeutics, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Ripple Therapeutics, Roche, Sanofi and Stealth BioTherapeutics, and is Editor in Chief of Eye. Tariq Aslam: Received funding/fees from Allergan, Apellis, Bayer, Canon, Heidelberg Engineering, Novartis, Roche, Théa and Topcon. Polona Jaki Mekjavić: Received honoraria for consultancy and lecture fees from AbbVie, Bayer, Novartis and Roche. Vilma Jūratė Balčiūnienė: Received personal fees/funding from AbbVie, Bayer, Novartis and Roche. Linda Visser: Received lecture fees from Alcon, Novartis and Roche. Antonia M. Joussen: Consultant for Bayer, Boehringer Ingelheim, Novartis and Roche, and received research funding from Bayer and Boehringer Ingelheim. Young Hee Yoon: Received honoraria for consultancy and lecture fees from Alcon, Allergan, Bayer HealthCare, Iveric and Roche, and grants from Bayer HealthCare, Celltrion, Kyowa Kirin, Opthea, Roche and Samsung Bioepis. Timothy Y. Y. Lai: Received personal fees from Alcon, Astellas, Bayer HealthCare, Boehringer Ingelheim, Chengdu Kanghong Biotech, Gaush Meditech, Iveric Bio, Novartis, Ocular Therapeutix, Oculis and Roche, and is a member of the Eye editorial board. Annabelle A. Okada: Received personal fees from 4D Molecular Therapeutics, Allergan Japan, Apellis, Astellas, Bayer Consumer Care, Chugai, Daiichi-Sankyo, Kowa, Novartis Pharma Japan, Ocular Therapeutix, Otsuka and Senju, grants and personal fees from Bayer Yakuhin, Mitsubishi Tanabe and Santen, and grants from Alcon Pharma Japan and Pfizer Japan.
